Alexandrine Garrigue

Alexandrine Garrigue

Auto-generated profile, based on publicly available information

Alexandrine Garrigue

INSERM UMR1163, Laboratory of Normal and Pathological Homeostasis of the Immune System, Paris, France; Paris Descartes University-Sorbonne Paris Cité, Imagine Institute, Paris, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2008 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
SHSalima Hacein-Bey-Abina
Salima Hacein-Bey-Abina
AGAlexandrine Garrigue
Alexandrine Garrigue
GWGary P. Wang
Gary P. Wang
JSJean Soulier
Jean Soulier
ALAnnick Lim
Annick Lim
MCMarina Cavazzana
Marina Cavazzana
Previously, several individuals with X-linked SCID (SCID-X1) were treated by gene therapy to restore the missing IL-2 receptor γ (IL2RG) gene to CD34+ BM precursor cells using gammaretroviral vectors. While 9 of 10 patients were successfully treated, 4 of the 9 developed T cell leukemia 31–68 months after gene therapy. In 2 of these cases, blast cells contained activating vector insertions near the LIM domain–only 2 (LMO2) proto-oncogene. Here, we report data on the 2 most recent adverse events, which occurred in patients 7 and 10. In patient 10, blast cells contained an integrated vector near LMO2 and a second integrated vector near the proto-oncogene BMI1. In patient 7, blast cells contained an integrated vector near a third proto-oncogene,CCND2. Additional genetic abnormalities in the patients’ blast cells included chromosomal translocations, gain-of-function mutations activating NOTCH1, and copy number changes, including deletion of tumor suppressor gene CDKN2A, 6q interstitial losses, and SIL-TAL1 rearrangement. These findings functionally specify a genetic network that controls growth in T cell progenitors. Chemotherapy led to sustained remission in 3 of the 4 cases of T cell leukemia, but failed in the fourth. Successful chemotherapy was associated with restoration of polyclonal transduced T cell populations. As a result, the treated patients continued to benefit from therapeutic gene transfer.

1 August 2007 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ADAnnette Deichmann
Annette Deichmann
SHSalima Hacein-Bey-Abina
Salima Hacein-Bey-Abina
MSManfred Schmidt
Manfred Schmidt
AGAlexandrine Garrigue
Alexandrine Garrigue
MBMartijn H. Brugman
Martijn H. Brugman
MCMarina Cavazzana
Marina Cavazzana
Recent reports have challenged the notion that retroviruses and retroviral vectors integrate randomly into the host genome. These reports pointed to a strong bias toward integration in and near gene coding regions and, for gammaretroviral vectors, around transcription start sites. Here, we report the results obtained from a large-scale mapping of 572 retroviral integration sites (RISs) isolated from cells of 9 patients with X-linked SCID (SCID-X1) treated with a retrovirus-based gene therapy protocol. Our data showed that two-thirds of insertions occurred in or very near to genes, of which more than half were highly expressed in CD34+ progenitor cells. Strikingly, one-fourth of all integrations were clustered as common integration sites (CISs). The highly significant incidence of CISs in circulating T cells and the nature of their locations indicate that insertion in many gene loci has an influence on cell engraftment, survival, and proliferation. Beyond the observed cases of insertional mutagenesis in 3 patients, these data help to elucidate the relationship between vector insertion and long-term in vivo selection of transduced cells in human patients with SCID-X1.

7 July 2016 in Blood
Verified
Journal Article
Open access
PDF file
SMSophia Maschalidi
Sophia Maschalidi
FSFernando E. Sepulveda
Fernando E. Sepulveda
AGAlexandrine Garrigue
Alexandrine Garrigue
AFAlain Fischer
Alain Fischer
GBGeneviève de Saint Basile
Geneviève de Saint Basile
Hemophagocytic lymphohistiocytosis is a life-threatening syndrome, characterized by severe hyperinflammation and immunopathological manifestations in several tissues. These features result from organ infiltration by over-activated CD8 T-cells and macrophages, which produce high levels of pro-inflammatory cytokines, such as IFN-γ, TNF-α, IL6 and IL18. Recently, several JAK1/2 inhibitors, such as ruxolitinib, have been developed as immunosuppressive agents. They have proven beneficial effects in the treatment of myeloproliferative disorders and inflammatory conditions. In order to determine whether pharmacological inhibition of the JAK1/2, not only prevents the onset of HLH immunopathology, but is effective against existing HLH, cytotoxicity-impaired Prf1-/- and Rab27a-/- mice with full-blown HLH syndrome were treated with a clinically relevant dose of ruxolitinib. In vivo, ruxolitinib treatment suppressed STAT1 activation and led to recovery from HLH manifestations in both murine models. In the Prf1-/- mice, these beneficial effects were evidenced by a greater survival rate, and in both murine models, by the correction of blood cytopaenia and a rapid decrease in serum IL6 and TNF-αlevels. During ruxolitinib treatment, liver tissue damage receded, concomitantly with a decrease in the number of infiltrating inflammatory macrophages and an increase in the number of alternatively activated macrophages. In Rab27a-/- mice, central nervous system involvement was significantly reduced by ruxolitinib therapy. Our findings demonstrate that clinically relevant doses of the JAK1/2 inhibitor ruxolitinib, suppresses the harmful consequences of macrophage over-activation characterizing HLH in two murine models. The results could be readily translated into the clinic for the treatment of primary and perhaps even secondary forms of HLH.

10 December 2007 in Journal of Experimental Medicine
Verified
Journal Article
Open access
ESEmmanuelle M. Six
Emmanuelle M. Six
DBDelphine Bonhomme
Delphine Bonhomme
MMMarta Monteiro
Marta Monteiro
KBKheira Beldjord
Kheira Beldjord
MJMonika Jurkowska
Monika Jurkowska
IAIsabelle André
Isabelle André
Identification of a thymus-seeding progenitor originating from human bone marrow (BM) constitutes a key milestone in understanding the mechanisms of T cell development and provides new potential for correcting T cell deficiencies. We report the characterization of a novel lymphoid-restricted subset, which is part of the lineage-negative CD34+CD10+ progenitor population and which is distinct from B cell–committed precursors (in view of the absence of CD24 expression). We demonstrate that these Lin−CD34+CD10+CD24− progenitors have a very low myeloid potential but can generate B, T, and natural killer lymphocytes and coexpress recombination activating gene 1, terminal deoxynucleotide transferase, PAX5, interleukin 7 receptor α, and CD3ε. These progenitors are present in the cord blood and in the BM but can also be found in the blood throughout life. Moreover, they belong to the most immature thymocyte population. Collectively, these findings unravel the existence of a postnatal lymphoid-polarized population that is capable of migrating from the BM to the thymus.

14 April 2008 in Nucleic Acids Research
Verified
Journal Article
Open access
GWGary P. Wang
Gary P. Wang
AGAlexandrine Garrigue
Alexandrine Garrigue
Angela CiuffiAngela Ciuffi
Angela Ciuffi
KRKeshet Ronen
Keshet Ronen
JLJeremy Leipzig
Jeremy Leipzig
FBFrederic D. Bushman
Frederic D. Bushman
Gene transfer has been used to correct inherited immunodeficiencies, but in several patients integration of therapeutic retroviral vectors activated proto-oncogenes and caused leukemia. Here, we describe improved methods for characterizing integration site populations from gene transfer studies using DNA bar coding and pyrosequencing. We characterized 160,232 integration site sequences in 28 tissue samples from eight mice, where Rag1 or Artemis deficiencies were corrected by introducing the missing gene with gamma-retroviral or lentiviral vectors. The integration sites were characterized for their genomic distributions, including proximity to proto-oncogenes. Several mice harbored abnormal lymphoproliferations following therapy--in these cases, comparison of the location and frequency of isolation of integration sites across multiple tissues helped clarify the contribution of specific proviruses to the adverse events. We also took advantage of the large number of pyrosequencing reads to show that recovery of integration sites can be highly biased by the use of restriction enzyme cleavage of genomic DNA, which is a limitation in all widely used methods, but describe improved approaches that take advantage of the power of pyrosequencing to overcome this problem. The methods described here should allow integration site populations from human gene therapy to be deeply characterized with spatial and temporal resolution.

26 February 2015 in Blood
Verified
Journal Article
Open access
PDF file
FSFernando E. Sepulveda
Fernando E. Sepulveda
SMSophia Maschalidi
Sophia Maschalidi
CVChristian A. J. Vosshenrich
Christian A. J. Vosshenrich
AGAlexandrine Garrigue
Alexandrine Garrigue
MKMathieu Kurowska
Mathieu Kurowska
GBGeneviève de Saint Basile
Geneviève de Saint Basile
Key Points: NK cytotoxic activity limits HLH-like immunopathology in cytotoxic-deficient mice. NK cytotoxic activity reduces T-cell activation and tissue infiltration of macrophages.